Welcome to LookChem.com Sign In|Join Free

CAS

  • or

58583-72-5

Post Buying Request

58583-72-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

58583-72-5 Usage

Explanation

The compound is composed of 12 carbon atoms, 12 hydrogen atoms, and 3 oxygen atoms.

Explanation

The compound features a carbonyl group (C=O) attached to a benzofuran ring, which is a fused ring system consisting of a benzene ring and a furan ring. Additionally, an ethoxy group (-O-CH2-CH3) is attached to the benzofuran ring.

Explanation

The compound has potential uses in the development of new drugs and materials due to its unique chemical structure and properties.

Explanation

The presence of the benzofuran ring in the compound may contribute to its potential for exhibiting interesting biological activities, which could be useful in the development of new drugs.

Explanation

Further investigation into the compound's potential uses and effects is necessary to fully understand its capabilities and potential applications in the pharmaceutical and materials science fields.

Explanation

The solubility of 1-(7-ethoxy-1-benzofuran-2-yl)ethanone in various solvents is not discussed in the provided material.

Explanation

The stability of the compound under different conditions, such as temperature, pressure, or in the presence of other chemicals, is not discussed in the provided material.

Explanation

The reactivity of 1-(7-ethoxy-1-benzofuran-2-yl)ethanone with other chemicals or under specific conditions is not discussed in the provided material.

Chemical Structure

Ketone with a benzofuran ring and an ethoxy group

Applications

Pharmaceutical and organic synthesis

Biological Activity

Potential for various biological activities

Research Significance

Importance for further research and studies

Solubility

Not mentioned in the material provided

Stability

Not mentioned in the material provided

Reactivity

Not mentioned in the material provided

Check Digit Verification of cas no

The CAS Registry Mumber 58583-72-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,5,8 and 3 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 58583-72:
(7*5)+(6*8)+(5*5)+(4*8)+(3*3)+(2*7)+(1*2)=165
165 % 10 = 5
So 58583-72-5 is a valid CAS Registry Number.
InChI:InChI=1/C12H12O3/c1-3-14-10-6-4-5-9-7-11(8(2)13)15-12(9)10/h4-7H,3H2,1-2H3

58583-72-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(7-Ethoxy-1-benzofuran-2-yl)ethanone

1.2 Other means of identification

Product number -
Other names HMS2672F20

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:58583-72-5 SDS

58583-72-5Downstream Products

58583-72-5Relevant articles and documents

Novel 1-(7-ethoxy-1-benzofuran-2-yl) substituted chalcone derivatives: Synthesis, characterization and anticancer activity

Coskun, Demet,Erkisa, Merve,Ulukaya, Engin,Coskun, Mehmet Fatih,Ari, Ferda

, p. 212 - 222 (2017)

Cancer treatment still requires new compounds to be discovered. Chalcone and its derivatives exhibit anticancer potential in different cancer cells. A new series of benzofuran substituted chalcone derivatives was synthesized by the base-catalyzed Claisen-

Selective agonist of dopamine D2 receptor (DRD2) and application thereof in treatment of diseases

-

Paragraph 0193-0195; 0197-0199, (2020/12/08)

The invention relates to a selective agonist of DRD2 and application thereof in treatment of diseases. Specifically, the invention discloses an agonist with high selectivity to DRD2 for the first time. The structure of the agonist is shown as a formula I.

NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

-

Page/Page column 27; 40, (2015/06/25)

The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 58583-72-5
  • ©2008 LookChem.com,License:ICP NO.:Zhejiang16009103 complaints:service@lookchem.com
  • [Hangzhou]86-571-87562588,87562561,87562573 Our Legal adviser: Lawyer